Newsletter Subject

The Key to One-Day Payouts

From

outsiderclub.com

Email Address

newsletter@outsiderclub.com

Sent On

Wed, Jan 10, 2024 04:30 PM

Email Preheader Text

As someone who focuses on the defense sector, I’m no stranger to massive one-day stock surges.

As someone who focuses on the defense sector, I’m no stranger to massive one-day stock surges. As someone who focuses on the defense sector, I’m no stranger to massive one-day stock surges.                                                                                                      [Outsider Club Header] Jan 09, 2024 By Jason Simpkins for the Outsider Club The Key to One-Day Payouts As someone who focuses on the defense sector, I’m no stranger to massive one-day stock surges. When Russia invaded Ukraine, my portfolio went bananas. When Hamas attacked Israel last October, it shot up again. And more recently, when shipping vessels came under fire from Iranian proxy groups, what do you think happened? Defense stocks surged. But here’s the thing… Even I — someone who’s been on the receiving end of these massive one-day defense stock explosions — can admit that they’re few and far in between. The simple fact is most defense stocks are already mammoth. So while they may steadily advance thanks to rising defense budgets and get juicy tailwinds whenever chaos breaks out… Those big-time, one-day shots don’t occur as often as I'd like. And if we’re being honest, that’s probably for the best. However, there is one investing sector where big, one-day blasts occur as a matter of routine… And that’s the biotech sector. That’s because when it comes to pharmaceuticals, there’s a litany of milestones that each and every product must hit before it goes to market. There’s an entire gauntlet of trials and tests that needs to be run before a drug can be prescribed safely. It’s an intense process and not every drug makes it through, but every hurdle that is cleared creates a massive profit tsunami for investors. And that happens more frequently than you might realize. "ChatGPT Tech Opened the Door for THIS" The AI technology behind ChatGPT is about to be unleashed in every industry you can think of... From high-tech fields like cybersecurity to low-tech industries like agriculture, as well as health care, finance, manufacturing — the list goes on and on. Companies in all of these industries are looking for ways to integrate AI into their operations. As the technology expands, it’s expected to boost the global economy by an incredible $15.7 trillion. One little-known firm is already working to make this vision into reality. I expect its stock to skyrocket from less than $10 to $215 FAST. This is the most exciting AI investment on the horizon — and you can be among the first to hear about it. [Get all the details here.]( In 2022, the FDA approved 37 new drugs, which means the government approved an average of three new treatments each month. Furthermore, there are nearly 880 publicly traded biotech companies currently developing a grand total of 8,000 new drugs as we speak. Each one of those 8,000 drugs has to go through all 12 steps of the FDA pipeline. And each of those 12 steps is a potential catalyst event that can send a biotech stock into the stratosphere. Do the math on that and it's 96,000 opportunities for investors to hit those single-day windfalls. Because each time one of these biotech companies clears one of these steps, it's a signal to the market — a clear indication that its drug or treatment is moving closer to becoming a money-minting machine. The next Lipitor or Ozempic. I’m not kidding you when I tell you these stock gains are wild, either. Celgene, for example, returned over 6,200% for investors before being taken over by Bristol-Myers Squibb. Questcor Pharmaceuticals skyrocketed a total of 33,428% as its novel treatments for autoimmune disorders blazed through the FDA pipeline one after another. It was then taken over by Mallinckrodt. (Buyouts and takeovers are another great catalyst for massive one-day stock gains.) And genetic sequencing superstar Illumina (NASDAQ: ILMN) has generated an eye-popping 47,618% in gains for investors throughout its history. Tesla Is Dead... Elon Musk Is Ruined Thanks to a new discovery — known as “Blue Gas” — electric car companies like Tesla are about to go down in flames. “Blue Gas” is 100% emission-free, can propel vehicles hundreds of miles, and allows cars to fully charge in just minutes. And the tiny company behind it is primed to absolutely shatter any gains ever paid out by Tesla. [Click here before this stock explodes in the coming months.]( Now, maybe you missed out on these gains and feel like you missed the boat… But if that’s the case, fear not… Because more opportunities like these are coming down the pike. Like I said, they hit every single month, as a matter of fact. And all you need to do to get in on the massive stock gains being generated is follow these drugs through the pipeline. One of the most successful investors I know has even built a calendar around these occurrences. [TT Catalyst Calendar Gains]( Better still, he’s in touch with a vast network of more than 250 scientists and doctors. [Check that out here]( and you’ll be cashing in in no time. Fight on, [Jason Simpkins Signature] Jason Simpkins P.S. Today’s article was originally published by our sister publication [Wealth Daily](. The editors of Wealth Daily offer their readers access to free moneymaking insights and opinions that cover the broad scope of the entire market. Whether it's stocks, bonds, commodities, or real estate, our editors work to provide investors with independent daily analysis they just can't find by following the mainstream media. [Sign up for their free daily email investment letter here.]( Follow the Outsiders [YouTube]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy[here](. Outsider Club, Copyright © Outsider Club LLC, 3 E Read Street Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-855-496-0830](tel:/18554960830).

Marketing emails from outsiderclub.com

View More
Sent On

08/12/2024

Sent On

06/12/2024

Sent On

04/12/2024

Sent On

03/12/2024

Sent On

02/12/2024

Sent On

26/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.